Compare Stocks: STRM, DMN, VRCA, and ICCC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMN Grafiti	$0.00	$0.00	$0.00 ▼ $4.95	$8K	0.04	231.68 million shs	N/A
ICCC ImmuCell	$9.90	$10.59	$4.52 ▼ $12.10	$89.91M	0.54	30,883 shs	11,695 shs
STRM Streamline Health Solutions	$5.33	$5.32	$2.07 ▼ $5.34	$23.23M	2.07	66,366 shs	N/A
VRCA Verrica Pharmaceuticals	$5.30	$5.46	$3.28 ▼ $9.82	$91.05M	1.49	107,463 shs	12,187 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMN Grafiti	0.00%	0.00%	0.00%	0.00%	-97.64%
ICCC ImmuCell	0.00%	-0.40%	-10.00%	+2.06%	+56.40%
STRM Streamline Health Solutions	0.00%	0.00%	0.00%	0.00%	0.00%
VRCA Verrica Pharmaceuticals	0.00%	-6.85%	+4.33%	-11.52%	+3.72%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMN Grafiti	$0.00	$0.00	$0.00 ▼ $4.95	$8K	0.04	231.68 million shs	N/A
ICCC ImmuCell	$9.90	$10.59	$4.52 ▼ $12.10	$89.91M	0.54	30,883 shs	11,695 shs
STRM Streamline Health Solutions	$5.33	$5.32	$2.07 ▼ $5.34	$23.23M	2.07	66,366 shs	N/A
VRCA Verrica Pharmaceuticals	$5.30	$5.46	$3.28 ▼ $9.82	$91.05M	1.49	107,463 shs	12,187 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMN Grafiti	0.00%	0.00%	0.00%	0.00%	-97.64%
ICCC ImmuCell	0.00%	-0.40%	-10.00%	+2.06%	+56.40%
STRM Streamline Health Solutions	0.00%	0.00%	0.00%	0.00%	0.00%
VRCA Verrica Pharmaceuticals	0.00%	-6.85%	+4.33%	-11.52%	+3.72%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMN Grafiti	0.00	N/A	N/A	N/A
ICCC ImmuCell	2.00	Hold	N/A	N/A
STRM Streamline Health Solutions	0.00	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	2.40	Hold	$12.67	138.99% Upside

Current Analyst Ratings Breakdown

Latest STRM, DMN, VRCA, and ICCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	VRCA Verrica Pharmaceuticals	Lake Street Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$9.00
8/18/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Hold (C-)
7/15/2026	VRCA Verrica Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/2/2026	ICCC ImmuCell	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMN Grafiti	$386.09K	0.02	N/A	N/A	$173.16 per share	0.00
ICCC ImmuCell	$30.68M	2.93	$0.19 per share	51.35	$2.99 per share	3.31
STRM Streamline Health Solutions	$18.38M	1.26	N/A	N/A	$2.87 per share	1.86
VRCA Verrica Pharmaceuticals	$35.58M	2.56	N/A	N/A	$1.55 per share	3.42

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMN Grafiti	-$45.95M	-$84.00	N/A	N/A	N/A	-874.43%	-1,561.96%	-160.38%	N/A
ICCC ImmuCell	-$1.04M	$0.08	123.77	N/A	N/A	2.57%	2.69%	1.76%	11/12/2026 (Estimated)
STRM Streamline Health Solutions	-$10.16M	-$2.28	N/A	N/A	N/A	-49.32%	-68.23%	-24.77%	N/A
VRCA Verrica Pharmaceuticals	-$17.89M	-$1.67	N/A	N/A	N/A	-102.84%	-407.11%	-70.17%	11/13/2026 (Estimated)

Latest STRM, DMN, VRCA, and ICCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	ICCC ImmuCell	$0.05	$0.20	+$0.15	$0.20	$5.40 million	$7.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMN Grafiti	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A
STRM Streamline Health Solutions	N/A	N/A	N/A	N/A	N/A
VRCA Verrica Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMN Grafiti	0.35	0.46	0.34
ICCC ImmuCell	0.22	4.75	2.71
STRM Streamline Health Solutions	N/A	0.27	0.27
VRCA Verrica Pharmaceuticals	0.18	1.45	1.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMN Grafiti	11.70%
ICCC ImmuCell	13.47%
STRM Streamline Health Solutions	31.74%
VRCA Verrica Pharmaceuticals	42.45%

Insider Ownership

Company	Insider Ownership
DMN Grafiti	0.34%
ICCC ImmuCell	5.70%
STRM Streamline Health Solutions	30.59%
VRCA Verrica Pharmaceuticals	52.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMN Grafiti	N/A	4.62 million	706,000	N/A
ICCC ImmuCell	70	9.08 million	8.56 million	Not Optionable
STRM Streamline Health Solutions	130	4.36 million	3.02 million	Not Optionable
VRCA Verrica Pharmaceuticals	40	17.18 million	8.09 million	No Data

STRM, DMN, VRCA, and ICCC Headlines

Recent News About These Companies

Verrica Pharmaceuticals (NASDAQ:VRCA) Coverage Initiated at Lake Street Capital

August 29, 2026 | americanbankingnews.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data ...

August 27, 2026 | finance.yahoo.com

Lake Street Capital Begins Coverage on Verrica Pharmaceuticals (NASDAQ:VRCA)

August 27, 2026 | marketbeat.com

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026 | globenewswire.com

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Receives Consensus Rating of "Hold" from Analysts

August 20, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Buys 4,200 Shares

August 19, 2026 | insidertrades.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CMO Noah Rosenberg Purchases 4,200 Shares of Stock

August 18, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) CEO Jayson Rieger Acquires 5,000 Shares

August 18, 2026 | marketbeat.com

Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to Strong Sell at Wall Street Zen

August 15, 2026 | marketbeat.com

Verrica (VRCA) Q2 2026 Earnings Call Transcript

August 14, 2026 | finance.yahoo.com

Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates

August 6, 2026 | zacks.com

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026 | manilatimes.netM

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026 | finance.yahoo.com

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026 | globenewswire.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum ...

July 21, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026 | globenewswire.com

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment ...

June 23, 2026 | markets.businessinsider.com

Verrica Pharmaceuticals Announces First U.S. and Japanese Patients Dosed in Phase 3 COVE-3 Trial of YCANTH for Common Warts

June 22, 2026 | quiverquant.comQ

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

June 22, 2026 | globenewswire.com

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRM, DMN, VRCA, and ICCC Company Descriptions

Grafiti NASDAQ:DMN

$0.0017 0.00 (0.00%)

As of 09/4/2026

Grafiti Holding is the holding company of Grafiti UK, which operates the Grafiti UK Business. Grafiti is a distributor in the UK and certain other European countries of data analytics and visualization software products referred to as “SAVES” primarily for scientists and engineers. Our products can be downloaded to a user's desktop. These products help scientific research in the health and life sciences domain in the discovery of new drugs, in the study of the efficacy of established drugs and therapies, and in epidemic propagation research, among other applications. Engineers use our products for a multitude of applications which include, but are not limited to, conducting surface modelling analysis and curve fitting in order to design new engineering processes, studying signal attenuation and propagation in radio engineering. Potential automobile and motorcycle applications could include surface panel design for aerodynamics, aesthetic symmetry, and calculated asymmetry among others. We believe our regression analysis product could also be used for predicting vehicle sharing demand and pricing trends in various markets based on a wide range of variables. Grafiti Holding was incorporated on October 17, 2023 in British Columbia, Canada. Grafiti UK was formed by the Parent on May 13, 2020 as a distribution arm for its SAVES products in the UK market and part of the European market. Grafiti UK's strategy is to build a broader, long term customer base by increasing its sales of Grafiti UK's product offerings which will include cloud and Macintosh compatible data analytics and statistical visualization software products. We believe this will enable the Grafiti UK Business to focus on generating more recurring revenues in the future. The address of our principal executive office is 268 Bath Road, Slough.

ImmuCell NASDAQ:ICCC

$9.90 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Streamline Health Solutions NASDAQ:STRM

Streamline Health Solutions, Inc. offers health information technology solutions and associated services for hospitals and health systems in the United States and Canada. The company offers RevID, an automated revenue reconciliation software; eValuator, a coding analysis platform; data comparison engine; coding and clinical documentation improvement (CDI) solutions, including CDI, abstracting, and physician query; and financial management solutions, such as accounts receivable management, denials management, claims processing, spend management, and audit management. It also provides auditing and coding, software, and professional services. The company sells its solutions and services through direct sales force and reseller partnerships. Streamline Health Solutions, Inc. was incorporated in 1989 and is based in Alpharetta, Georgia.

Verrica Pharmaceuticals NASDAQ:VRCA

$5.30 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STRM, DMN, VRCA, and ICCC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STRM, DMN, VRCA, and ICCC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STRM, DMN, VRCA, and ICCC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRM, DMN, VRCA, and ICCC Company Descriptions

Grafiti NASDAQ:DMN

ImmuCell NASDAQ:ICCC

Streamline Health Solutions NASDAQ:STRM

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest STRM, DMN, VRCA, and ICCC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest STRM, DMN, VRCA, and ICCC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

STRM, DMN, VRCA, and ICCC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

STRM, DMN, VRCA, and ICCC Company Descriptions

Grafiti NASDAQ:DMN

ImmuCell NASDAQ:ICCC

Streamline Health Solutions NASDAQ:STRM

Verrica Pharmaceuticals NASDAQ:VRCA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools